Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...

This acquisition marks a significant step in Jubilant Biosys' global strategy, providing a foothold in Europe's expanding ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a pharmaceutical company specializing in treatments for tumors and viruses, has initiated the exercise of existing warrants which is expected to ...

European equities traded in the US as American depositary receipts were tracking slightly lower late Thursday morning, declining 0.04% to 1,402.70 on the S&P Europe Select ADR Index. From continental ...

The risk of pharma bribery, the risk of brain drain, and other risks (and rewards) in the biotech landscape this week.

Investment trusts have a number of tricks up their sleeves that mean they can boost their dividend payouts. This is what to ...

President Donald Trump signed a memo Thursday directing his administration to start determining what level of reciprocal ...

Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

Researchers have successfully uncovered the molecular mechanisms by which bacterial cellulose patches stimulate the regeneration of plant wounds.   - The regeneration process requires the activation ...